Gossamer Bio's seralutinib shows promise in PAH Phase 2 trials, but Phase 3 success is vital amidst competition. Click to ...

SAN DIEGO, May 07, 2025--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for ...

Following its presentation at the ATS 2025 International Conference, the poster will also be made available on the "Posters & Publications" section of the Gossamer Bio website at gossamerbio.com ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Gossamer Bio (NASDAQ:GOSS – Free Report) had its target price cut by The Goldman Sachs Group from $8.00 to $7.00 in a research report sent to investors on Thursday,Benzinga reports.They ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension ...